LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

SectorHealthcare

66.74 -0.12

Buy Sell

Overview

Share price change

24h

Current

Min

65.3

Max

68.8

Key metrics
By Trading Economics
Income	292M 150M
Sales	-75M 377M
P/E Sector Avg	24.112 50.102
EPS	1.221
Profit margin	39.832
Employees	423
EBITDA	-63M 218M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+25.92% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	501M 8.2B
Previous open	66.86
Previous close	66.74

News Sentiment

By Acuity

13%

87%

15 / 344 Healthcare

Halozyme Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Jun 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 Jun 2026, 23:38 UTC

Acquisitions, Mergers, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 Jun 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 Jun 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Jun 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 Jun 2026, 22:08 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 Jun 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 Jun 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 Jun 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 Jun 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 Jun 2026, 21:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 Jun 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 Jun 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jun 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 Jun 2026, 20:46 UTC

Acquisitions, Mergers, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 Jun 2026, 20:22 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 Jun 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 Jun 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 Jun 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 Jun 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 Jun 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 Jun 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 Jun 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 Jun 2026, 18:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 Jun 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 Jun 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 Jun 2026, 18:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 Jun 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 Jun 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Jun 2026, 17:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

25.92% upside

12 Months Forecast

Average 85.8 USD 25.92%

High 96 USD

Low 70 USD

Based on 5 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

15 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.